REPORT

13th ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY

Chairs: N. Pavlidis, GR - R. A. Stahel, CH
Scientific Coordinators: W. Gatzemeier, IT - R. Popescu, CH
Course coordination / Management: F. Marangoni, IT

8-13 March 2014 Ermatingen (Lake Constance), Switzerland

The Masterclass was held for the sixth time as a joint venture with ESMO, the European Society for Medical Oncology (www.esmo.org), for the seventh time with EONS the European Oncology Nursing Society (www.cancernurse.eu), and for the third time as part of the Master-Online Study Program in Advanced Oncology of the University of Ulm (www.uni-ulm.de/med/masteroncology.html)
The Masterclasses were held in collaboration con the Flims Alumnis Club (http://www.ecco-org.eu/About-Ecco/Members/FLIMS)

AIMS AND OBJECTIVES
This clinically oriented educational programme has been designed for medical or clinical oncologists who wish to improve their skills or those who are preparing for the national board exam. The programme exposed participants to a full spectrum of issues in clinical oncology and to practice-oriented training. The core clinical sessions of the programme focused on genito-urinary, gastro-intestinal, breast, gynaecological, head and neck and lung cancers.

The 13th Masterclass spotlight sessions facilitated compact update on: new oncological emergencies, supportive care, skin toxicities, the role of PET in oncology, cancer of unknown primary, biology of cancer, bone health and cancer, cancer and kidney, fertility preservation, sarcomas and GIST, health economics, haematological diseases - focus on lymphomas and myeloma, state of the art approaches to brain tumours, bio-informatics, and advances in systemic treatment of melanoma. Special joint sessions were dedicated to survivorship - challenges over time, introduction to communication skills, and facilitating patient adherence to oral cancer therapies.
TEACHING FORMAT
The Masterclass offered plenary lectures regarding state-of-the-art clinical evaluation and treatments with reference to clinical guidelines and which concluded in take-home messages. The Clinical Sessions were complemented by Tumour Board discussions. Furthermore, participants delivered case presentations within small groups and discussed these with the chairmen and the faculty. All participants resided at the course venue and participation was compulsory throughout the course. The Masterclass was entirely in English and fluency in English was necessary for admission. Participants of the concomitant Masterclass in Nursing Oncology attended selected medical sessions whilst the sessions on survivorship - challenges over time, introduction to communication skills, and facilitating patient adherence to oral cancer therapies were attended jointly.

THE MASTERCLASS is:
• A 5-day residential educational event
• Full immersion in clinical oncology
• Clinically-oriented
• Multidisciplinary
• An international faculty of top experts delivering lectures focusing on genito-urinary, breast, gynaecological, head and neck, gastro-intestinal and lung cancers.

ACCREDITATION
The Accreditation Council of Oncology in Europe (ACOE) and the European Accreditation Council for Continuing Medical Education (EACCME) have acknowledged the quality of the scientific programme and its educational value. The 13th ESO-ESMO Masterclass in Clinical Oncology has been assigned 30 European Continuing Medical Education Credits (ECMEC).
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.amaassn.org/go/internationalcme.

Furthermore, the Masterclass has been accredited with 25 ESMO-MORA points Category 1. www.esmo.org

ACKNOWLEDGEMENTS
ESO wishes to express its appreciation Wolfsberg Centre for their consideration and support to the 2012 Masterclass.

The Masterclass is part of the Sharing Progress in Cancer Care (SPCC) programme whose sustaining members are:

• Platinum members: Amgen
• Gold members: Eli Lilly, GlaxoSmithKline Oncology, Helsinn, Merck Serono, Novartis Oncology and Roche
• Silver members: Boehringer Ingelheim, Celgene Corporation, Eisai, Genomic Health and Sanofi Oncology
ESO thanks the Flims Alumni Club for the collaboration in promoting the Masterclass.
PROGRAMME:

8 March

12:30 **Lunch**

14:00 **Focus on ESO and on ESMO**
   A. Costa, IT - R.A. Stahel, CH

14:30 Warm-up session in groups

15:00 **Clinical session Genito-urinary cancers I**
   **Chair:** K. Fizazi, FR
   **Prostate cancer:**
   - Local therapy: Surgery and radiotherapy
     A. Horwich, UK
   - First-line endocrine treatment
     A. Horwich, UK
   - Endocrine resistant - refractory
     K. Fizazi, FR

16:30 **Coffee break**

9 March

8:30 **Clinical session Gastro-intestinal tumours I**
   **Chair:** D. Sebag-Montefiore, UK
   **Colon cancer:**
   - Adjuvant and neoadjuvant treatment of colorectal cancer
     E. Van Cutsem, BE
   - Systemic treatment in advanced disease (including liver)
     E. Van Cutsem, BE

10:00 **Coffee break**

10:30 **Clinical session Gastro-intestinal tumours II**
   **Chair:** A. Cervantes, ES
   - Management of rectal cancer (surgery and radiotherapy)
     D. Sebag-Montefiore, UK
   - Systemic treatment in early and advanced gastric cancer (including pancreas)
     A. Cervantes, ES
   - **Pancreatic Cancer**
     R. Popescu, CH

12:00 **Tumour board Gastro-intestinal tumours**
   A. Cervantes, ES - D. Sebag-Montefiore, UK - R. Popescu, CH - E. Van Cutsem, BE

13:00 **Lunch**

14:00 **Spotlight session 1 New oncological emergencies**
   B. Pestalozzi, CH

14:45 **Spotlight session 2 Supportive care**
   M. Aapro, CH

15:30 **Spotlight session 3 Skin toxicities of new targeted drugs**

16:00 **Coffee break**

16:30 **Spotlight session 4 The role of PET in oncology**
   B. Krause, DE

17:00 **Case presentations by participants**

19:30 **Dinner**
10 March

8:30  Clinical session Breast cancer I  
Chair: G. Curigliano, IT  
- What the clinician needs to know about breast pathology  
  G. Pruneri, IT  
- (Neo)Adjuvant chemotherapy and biological agents  
  G. Curigliano, IT  
- (Neo)Adjuvant endocrine therapy  
  O. Pagani, CH  
- Current controversies and challenges in breast surgery  
  W. Gatzemeier, IT

10:10  Coffee break

10:40  Clinical session Breast cancer II  
Chair: O. Pagani, CH  
- Management of HER-2+ and triple negative advanced breast cancer  
  G. Curigliano, IT  
- Management of ER+ advanced breast cancer  
  O. Pagani, CH  
- Standards and new techniques in breast radiotherapy  
  J. Bernier, CH

12:00  Tumour board Breast cancer  
G. Pruneri, IT - G. Curigliano, IT - J. Bernier, CH - O. Pagani, CH - W. Gatzemeier, IT

13:00  Lunch

14:30  Spotlight session 5 Cancer of unknown primary  
N. Pavlidis, GR

14:45  Spotlight session 6 Biology of cancer  
S. Peters, CH

15:15  Spotlight session 7 Bone health and cancer  
S. Peters, CH

15:45  Coffee break

16:15  Case presentation by participants

17:45  Focus on ESO and on ESMO  
A. Costa, IT - R.A. Stahel, CH

18:15  Cancer and kidney  
V. Launay-Vacher, FR

19:30  Dinner
11 March

8:30 Clinical session Gynaecological cancers
Chair: J.B. Vermorken, BE

• Ovarian cancer
  J.B. Vermorken, BE
• Cervical and endometrial cancers
  C. Sessa, CH

10:00 Spotlight session 8 Fertility Preservation
  F.A. Peccatori, IT

10:30 Coffee break

11:00 Clinical session Head and neck cancer
Chair: J.B. Vermorken, BE

• Prognostic factors and surgical approach
  A. Dietz, DE
• Radiotherapy
  J. Bernier, CH
• Systemic therapy and radio-chemo-therapy
  J.B. Vermorken, BE

12:45 Lunch

13:45 Tumour board Gynaecological cancers
  J.B. Vermorken, BE - C. Sessa, CH

14:15 Tumour board Head and neck cancer
  J. Bernier, CH - A. Dietz, DE - J.B. Vermorken, BE

14:45 Spotlight session 9 Sarcomas and GIST
  P. Casali, IT

15:30 Spotlight session 10 Health economics
  T. Szucz, CH

16:00 Spotlight session 11 Haematological diseases
  S. Stilgenbauer, DE

16:30 Free time

19:00 Special evening
12 March

8:30 Clinical session Lung cancer and mesothelioma I
   Chair: R. Stahel, CH
   - Surgery
     W. Weder, CH
   - Radiotherapy
     C. Faivre-Finn, UK
   - Non-small cell lung cancer systemic therapy
     R.A. Stahel, CH

10:30 Coffee break

11:00 Clinical session Lung cancer and mesothelioma II
   Chair: R.A. Stahel, CH
   - Small cell lung cancer
     C. Faivre-Finn, UK
   - Mesothelioma
     R.A. Stahel, CH

12:00 Tumour board Lung cancer
   R.A. Stahel, CH - W. Weder, CH - C. Faivre-Finn, UK
13:00 Lunch

14:00 Case presentations by participants

15:30 Spotlight session 12 State of the art approaches to brain tumours
   N. Weiler, CH

16:00 Spotlight session 13 Bio-informatics
   O. Mühlen, CH

16:30 Coffee break

17:00 Spotlight session 14 Melanoma
   O. Mühlen, CH

17:45 Learning assessment test

19:30 Dinner

13 March

8:30 JOINT session MCO + MON I parallel sessions
   (2 groups, each group attending both parts)

GROUP A
   - Introduction to Communication Skills - an interactive learning workshop
     A. Arber, UK - A. Hoy, UK

GROUP B
   - Facilitating patient adherence to oral cancer therapies
     C. Rothermundt, CH
   - Survivorship - challenges over time
     N. Aaronson, NL

10:00 Coffee break

10:30 JOINT session MCO + MON II parallel sessions
   (2 groups, each group attending both parts)

GROUP B
   - Facilitating patient adherence to oral cancer therapies
     C. Rothermundt, CH
   - Survivorship - challenges over time
     N. Aaronson, NL

GROUP A
   - Introduction to Communication Skills - an interactive learning workshop
     A. Arber, UK - A. Hoy, UK

12:00 Close
ATTENDANCE TO THE MASTERCLASS

Attendance to the masterclass was by application only. Successful applicants were granted free registration and accommodation. **Application deadline was 1 DECEMBER 2013**

**Ideal Masterclass candidate profile:**
- Age between 30 and 40 years
- At least 2-3 years’ experience in medical oncology or clinical oncology
- Involvement in scientific activities
- Fluency in English

**APPLICATION PROCEDURE:**
Candidates had to fill in the application form ([www.eso.net](http://www.eso.net)) providing:
- Letter describing motivation for attending
- CV with list of publications
- Supporting letter from head of department or mentor
- Clinical case relating to one of the subjects of the Masterclass

**COURSE STATISTICS**

93 Applications received  
60 Participants selected (56 out of 60 completed the evaluation sheet)  
33 Faculty members  
6 Observers from SPCC Members

**Participants Statistics**

**SPECIALITY**

<table>
<thead>
<tr>
<th>Speciality</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical Oncology</td>
<td>47</td>
</tr>
<tr>
<td>Clinical Oncology</td>
<td>7</td>
</tr>
<tr>
<td>RT Oncology</td>
<td>1</td>
</tr>
<tr>
<td>Cancer Research</td>
<td>1</td>
</tr>
</tbody>
</table>

**AGE AND GENDER**

<table>
<thead>
<tr>
<th>Gender</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>35</td>
</tr>
<tr>
<td>Male</td>
<td>21</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Date of birth</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Under 35</td>
<td>42</td>
</tr>
<tr>
<td>35-45</td>
<td>13</td>
</tr>
<tr>
<td>Over 45</td>
<td>1</td>
</tr>
</tbody>
</table>
EVALUATION OF THE 12th MASTERCLASS IN CLINICAL ONCOLOGY

13th ESO-ESMO Masterclass in Clinical Oncology

Ermatingen, Switzerland - 8/13 March 2014

Event Evaluation

General

How would you rate the following statement? The Masterclass offers participants a qualified training in clinical oncology to improve their knowledge in epidemiology, prevention, diagnosis, treatment and care in the field.

A) Poor: 0
B) Fair: 0
C) Good: 7
D) Excellent: 49

How would you rate the following statement? Attendees improve their skills in dealing with cancer problems as a whole challenge and gain more security to intercourse with them in sense of current best clinical practice and state of the art.

A) Poor: 0
B) Fair: 1
C) Good: 13
D) Excellent: 42

Please give an overall rating for the quality of the education offered at this meeting.

A) Poor: 0
B) Fair: 0
C) Good: 9
D) Excellent: 47
SUMMARY:

Participants appreciated the high level of this educational event and the broad opportunities for informal discussion with the faculty during sessions and beyond. Mediating oncological knowledge and principles in this way of full immersion in modern oncology created a collective spirit of teaching and learning to improving clinical skills and patient care. The evaluation of the participants opinion (questionnaire focussing on programme objectives, programme organisation, course organisation, facilities, and faculty) indicated that the Masterclass met the needs of the participants on most of the items and highlighted the necessity of such an event. The results of this evaluation will be in particular useful to further improve the upcoming 14th Masterclass which will be held in March 7-12, 2015.
The European School of Oncology (ESO) is an independent organisation. It recognises that the industrial partners are crucial for the delivery of best cancer care and fosters the continuation of the dialogue and identification of synergies. It restrains, however, the influence of marketing and strives to maintain its independence from the sponsors with whom it interacts with a neutral approach. Since its inauguration in 1982, ESO has been promoting cancer education in Europe and abroad. The original idea of the school is to fight against cancer in optimising training and updating competence of physicians and health care workers dealing with cancer patients in providing them with a comprehensive understanding of oncology - covering all aspects from epidemiology, screening, primary and secondary prevention, molecular-biology, diagnostic procedures, interdisciplinary treatment modalities, rehabilitation, palliative care, to psycho-oncological skills and promoting the importance of controlled randomised trials in clinical oncology. ESO’s mission is reflected in its
motto "Learning to Care", which stresses the concept of studying and learning and also of caring for the patient in a global sense. By improving the skills of all health professionals dealing with cancer patients, ESO shortens the length of time needed to transfer knowledge from advanced research centres to daily practice, combining advanced technology with humanism in care.

Wolfgang Gatzemeler, M.D.
ESO Masterclass Scientific Co-ordinator

2014 Masterclass in Clinical Oncology and Masterclass in Oncology Nursing Group-Photo
Faculty: Masterclass in Clinical Oncology and Masterclass in Oncology Nursing

The European School of Oncology would like to heartedly thank all faculty members, for having granted their expertise and dedication in providing this educational programme and making the 13th Masterclass a great success.

FACULTY

H. Aapro, Clinique de Genolier, Genolier, CH
A. Aaronson, Antoni van Leeuwenhoek Hospital, Department of Psychosocial Research and Epidemiology, Amsterdam, NL
A. Arber, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK
J. Bernier, Clinique de Genolier, Department of Radiotherapy, Genolier, CH
P. Casali, National Cancer Institute, Department of Medical Oncology, Milano, IT
A. Cervantes, Hospital Clinico Universitario, Department of Medical Oncology, Valencia, ES
A. Costa, European School of Oncology, Milan, IT
G. Curigliano, European Institute of Oncology, Division of Medical Oncology, Milano, IT
A. Dietz, University Hospital Leipzig, ENT Department, Leipzig, DE
T. Eisen, University of Cambridge, Department of Oncology, Cambridge, UK
C. Faivre-Finn, The Christie NHS Foundation Trust, Department of Clinical Oncology, Manchester, UK
K. Fizazi, Institut Gustave Roussy, Department of Cancer Medicine, Villejuif, FR
W. Gatzele, Humanitas Cancer Center, Breast Unit, Rozzano, IT
Y. Launay-Vacher, CHU Pitié-Salpétrière, Department of Nephrology, Paris, FR
A. Horwich, The Royal Marsden Hospital - Institute of Cancer Research, Division of Radiotherapy and Imaging Sutton, UK
A. Hoy, Consultant in Palliative Medicine, Lead for Advanced Communication Skills SWSH, Epsom, UK
H. Huddart, The Institute of Cancer Research (ICR) - Royal Marsden Hospital, Division of Radiotherapy and Imaging, Sutton, Surrey, UK
B. Krause, Medicine University Rostock, Clinic and Polyclinic for Nuclear Medicine, Rostock, DE
O. Michielin, Lausanne University Hospital - CHUV, Department of Medical Oncology, Lausanne, CH
O. Pagani, Oncology Institute of Southern Switzerland (IOSI), Breast Unit, Bellinzona, CH
N. Pavlidis, University Hospital of Ioannina, Division of Medical Oncology, Ioannina, GR
P.A. Pecorari, European Institute of Oncology, Division Gynecologic Oncology, Milano, IT
B. Pestalozzi, UniversitätsSpital, Oncology Clinic, Zurich, CH
S. Peters, Centre Hospitalier Universitaire Vaudois, Department of Oncology, Lausanne, CH
R. Popescu, Hirlanden Klinik Aarau, Tumor Center - Department of Medical Oncology, Aarau, CH
G. Pruneri, European Institute of Oncology, Pathology Division, Milano, IT
C. Rothermundt, Kantonsspital St. Gallen, Department of Oncology/Hematology, St. Gallen, CH
D. Sebag-Montefiore, St James’s Institute of Oncology - St James’ University Hospital, Department of Medical Oncology, Leeds, UK
S. Segaert, University Hospital Sint-Rafael, Department of Dermatology, Leuven, BE
C. Sessa, Oncology Institute of Southern Switzerland, Division of Medical Oncology, Bellinzona, CH
R.A. Stahel, University Hospital Zurich, Clinic for Oncology, Zurich, CH
S. Stijgenbauer, University of ULM, Dept. of Internal Medicine 3, Haematology and Oncology, ULM, DE
T. Szucs, Basel University, Institute of Pharmaceutical Medicine, Basel, CH
E. Van Cutsem, University Hospital Gasthuisberg, Department of Internal Medicine, Leuven, BE
J.B. Vermorken, University Hospital Antwerp, Department of Medical Oncology, Edegem, BE
W. Weder, University Hospital Zurich, Division of Thoracic Surgery, Zurich, CH
M. Woller, University Hospital Zurich, Department of Neurosurg, Zurich, CH